Shi Lan, Zhang Shanshan, Liu Gan, Nie Zhengchao, Ding Pengsheng, Chang Wenjiao, Dai Yuanyuan, Ma Xiaoling
Department of Clinical Laboratory, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Department of Medical Oncology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
J Biol Chem. 2025 Feb;301(2):108148. doi: 10.1016/j.jbc.2024.108148. Epub 2024 Dec 28.
Hepatocellular carcinoma (HCC) is one of the common malignant tumors. Complement system has become a new focus of cancer research by changing the biological behavior of cancer cells to influence the growth of cancer. Recent studies reported that the complement C5a-C5aR1 axis can promote the malignant phenotype of multiple tumors through various signaling pathways. LukS-PV (Panton-Valentine), the S component of Staphylococcus aureus-secreted PV leucocidin, can also bind C5aR1 specifically. This project aims to investigate the role of LukS-PV on HCC cell proliferation and explore underlying molecular mechanisms. Our findings revealed that LukS-PV targeting C5aR1 inhibited HCC cell proliferation in vitro and in vivo. Interestingly, we discovered that LukS-PV inhibited the proliferation of HCC cells by upregulating the acetylation level of β-catenin to promote its protein degradation. In addition, histone deacetylase (HDAC)7 identified as a regulator mediates the deacetylation of β-catenin. Furthermore, our results showed that LukS-PV inhibited proliferation in HCC cells by downregulating HDAC7 to promote the degradation of β-catenin through ubiquitin-proteasome system. Collectively, our findings revealed that LukS-PV targeting C5aR1 inhibits HCC cell proliferation through the HDAC7-Wnt/β-catenin axis. These results revealing a novel mechanism that LukS-PV as a bacterial toxin inhibits HCC cell proliferation through epigenetic remodeling by targeting complement receptor C5aR1, suggest the strong potential of LukS-PV as a promising candidate for HCC treatment.
肝细胞癌(HCC)是常见的恶性肿瘤之一。补体系统通过改变癌细胞的生物学行为影响肿瘤生长,已成为癌症研究的新热点。近期研究报道,补体C5a-C5aR1轴可通过多种信号通路促进多种肿瘤的恶性表型。金黄色葡萄球菌分泌的杀白细胞素PV(LukS-PV)的S成分也能特异性结合C5aR1。本项目旨在研究LukS-PV对肝癌细胞增殖的作用并探索其潜在分子机制。我们的研究结果显示,靶向C5aR1的LukS-PV在体外和体内均抑制肝癌细胞增殖。有趣的是,我们发现LukS-PV通过上调β-连环蛋白的乙酰化水平促进其蛋白降解,从而抑制肝癌细胞增殖。此外,组蛋白去乙酰化酶(HDAC)7被确定为介导β-连环蛋白去乙酰化的调节因子。再者,我们的结果表明,LukS-PV通过下调HDAC7,促进β-连环蛋白经泛素-蛋白酶体系统降解,从而抑制肝癌细胞增殖。总体而言,我们的研究结果显示,靶向C5aR1的LukS-PV通过HDAC7-Wnt/β-连环蛋白轴抑制肝癌细胞增殖。这些结果揭示了一种新机制,即LukS-PV作为一种细菌毒素,通过靶向补体受体C5aR1进行表观遗传重塑来抑制肝癌细胞增殖,提示LukS-PV作为肝癌治疗的有前景候选物具有强大潜力。